Format

Send to

Choose Destination
See comment in PubMed Commons below
Endocr Relat Cancer. 2008 Sep;15(3):649-56. doi: 10.1677/ERC-08-0043. Epub 2008 Jun 4.

Endocrine disruptors and prostate cancer risk.

Author information

1
Department of Urology, University of Illinois at Chicago, Chicago, Illinois 60612, USA. gprins@uic.edu

Abstract

There is increasing evidence both from epidemiology studies and animal models that specific endocrine-disrupting compounds may influence the development or progression of prostate cancer. In large part, these effects appear to be linked to interference with estrogen signaling, either through interacting with ERs or by influencing steroid metabolism and altering estrogen levels within the body. In humans, epidemiologic evidence links specific pesticides, PCBs and inorganic arsenic exposures to elevated prostate cancer risk. Studies in animal models also show augmentation of prostate carcinogenesis with several other environmental estrogenic compounds including cadmium, UV filters and BPA. Importantly, there appears to be heightened sensitivity of the prostate to these endocrine disruptors during the critical developmental windows including in utero and neonatal time points as well as during puberty. Thus infants and children may be considered a highly susceptible population for ED exposures and increased risk of prostate cancers with aging.

PMID:
18524946
PMCID:
PMC2822396
DOI:
10.1677/ERC-08-0043
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center